Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

por Leonardi, C, Menter, A, Hamilton, T, Caro, I, Xing, B, Gottlieb, AB
Publicado 2008

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis

por Gottlieb, AB, Langley, RG, Strober, BE, Papp, KA, Klekotka, P, Creamer, K, Thompson, EHZ, Hooper, M, Kricorian, G
Publicado 2012

Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials

por Blauvelt, A., Reich, K., Lebwohl, M., Burge, D., Arendt, C., Peterson, L., Drew, J., Rolleri, R., Gottlieb, A.B.
Publicado 2018

Tumour necrosis factor‐α inhibition can stabilize disease in progressive vitiligo

por Webb, K.C., Tung, R., Winterfield, L.S., Gottlieb, A.B., Eby, J.M., Henning, S.W., Le Poole, I.C.
Publicado 2015

Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III r...

por Gottlieb, A.B., Lacour, J.‐P., Korman, N., Wilhelm, S., Dutronc, Y., Schacht, A., Erickson, J., Zhang, L., Mallbris, L., Gerdes, S.
Publicado 2016

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

por Gordon, K.B., Warren, R.B., Gottlieb, A.B., Blauvelt, A., Thaçi, D., Leonardi, C., Poulin, Y., Boehnlein, M., Brock, F., Ecoffet, C., Reich, K.
Publicado 2020

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind hea...

por Gottlieb, A.B., Merola, J.F., Reich, K., Behrens, F., Nash, P., Griffiths, C.E.M., Bao, W., Pellet, P., Pricop, L., McInnes, I.B.
Publicado 2021

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies

por Blauvelt, A., Paul, C., van de Kerkhof, P., Warren, R.B., Gottlieb, A.B., Langley, R.G., Brock, F., Arendt, C., Boehnlein, M., Lebwohl, M., Reich, K.
Publicado 2020

Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials

por Strober, B.E., Gottlieb, A.B., van de Kerkhof, P.C.M., Puig, L., Bachelez, H., Chouela, E., Imafuku, S., Thaçi, D., Tan, H., Valdez, H., Gupta, P., Kaur, M., Frajzyngier, V., Wolk, R.
Publicado 2018